methyldi(2-thienyl)(chloromethyl)silane | 78599-05-0

• 英文名称: methyldi(2-thienyl)(chloromethyl)silane
• 英文别名: Methyl-di(2-thienyl)chloromethylsilane
• CAS: 78599-05-0
• 化学式: C₁₀H₁₁ClS₂Si
• 分子量: 258.868
• InChiKey: GDKAVSZPKWTOTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.78
• 重原子数：
  14.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  methyldi(2-thienyl)(chloromethyl)silane 、 3-(苯并咪唑-1-基)丙基-三甲基硅烷 以 甲苯 为溶剂， 反应 4.0h， 生成 N-methyl-N'-(3-trimethylsilylpropyl)benzimidazolium chloride
  参考文献：
  名称：

  Synthesis and antitumour activity of trimethylsilylpropyl substituted benzimidazoles

  摘要：

  The quaternisation of N-substituted benzimidazoles by heating with various alkyl, allyl, propargyl and benzyl chlorides and bromides leads to the formation of benzimidazolinium salts. The interaction of N-monosubstituted benzimidazoles with various salts (CuCl2, ZnCl2, CoCl2, PdCl2, and AgNO3) Yielded stable sol-id complexes. Potential cytotoxic activity of synthesised benzimidazolinium salts and benzimidazole metal complexes was tested in vitro on four monolayer tumour cell Hues: MG-22A (mouse hepatoma), HT-1080 (human fibrosarcoma), B16 (mouse melanoma), Neuro 2A (mouse neuroblastoma) and normal mouse fibroblast cells. A preliminary analysis of the structure-activity relationship for the benzimidazole derivatives clearly indicates that the character of substituents in the benzimidazole ring has strong influence on the cytotoxic activity. The insertion of the silicon atom into the N-alkyl chain increases the cytotoxic activity of benzimidazolinium salts significantly, which show a very significant potency in vitro against all studied tumour cell lines, being particularly active in experiments with B16 (mouse melanoma). TD, for the most active compounds are in the range 0.001-0.008 mug ml(-1). Cytotoxicity of benzimidazole metal complexes (L2MX2) strongly depends on the metal nature. 1-(3-Trimethylsilylpropyl)benzimidazole in dose 1 mg kg(-1) inhibits carcinoma S-180 tumour growth by 62% (on ICR mice). (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01241-7